Skip to content

(1st treatment: total 6 times, every weeks) Day 1: Select peptide candidates (up to 4), to which peptide-specific IgGs are detected before vaccination, and administer peptides that showed the highe

12 trials

Sponsors

Kurume University Cancer Vaccine Center, Kurume University School of medicine, Department of Immunology

Conditions

Biliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer)Hepatocellular carcinomaPancreatic cancerProstate cancerRenal cell carcinomaScirrhous gastric cancerUrotherial cancerbreast cancer

Phase 2

Phase II clinical trial of personalized peptide vaccination for advanced breast cancer
Active, not recruitingJPRN-UMIN000001844
Kurume University Cancer Vaccine Centerbreast cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for primary lung cancer
Active, not recruitingJPRN-UMIN000001839
Kurume University Cancer Vaccine Centerprimary lung cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for refractory cervical cancer patients
Active, not recruitingJPRN-UMIN000001847
Kurume University Cancer Vaccine Centercervical cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for ovarian cancer patients
Active, not recruitingJPRN-UMIN000001856
Kurume University Cancer Vaccine Centerovarian cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic renal cell carcinoma failed to standard treatment
Active, not recruitingJPRN-UMIN000001855
Kurume University School of medicine, Department of ImmunologyRenal cell carcinoma
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for hormone refractory prostate cancer patients
Active, not recruitingJPRN-UMIN000001850
Kurume University School of medicine, Department of ImmunologyProstate cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic urotherial cancer failed to standard treatment
Active, not recruitingJPRN-UMIN000001854
Kurume University School of medicine, Department of ImmunologyUrotherial cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for malignant brain tumor patients
Active, not recruitingJPRN-UMIN000001875
Kurume University Cancer Vaccine Centermalignant brain tumor
Start: 2009-04-01Target: 60Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for standard therapy failed or unoperable Pancreatic cancer patients
Active, not recruitingJPRN-UMIN000001881
Kurume University Cancer Vaccine CenterPancreatic cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for standard chemotherapy failed scirrhous gastric cancer patients
Active, not recruitingJPRN-UMIN000001883
Kurume University Cancer Vaccine CenterScirrhous gastric cancer
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for standard therapy failed Hepatocellular carcinoma patients
Active, not recruitingJPRN-UMIN000001882
Kurume University Cancer Vaccine CenterHepatocellular carcinoma
Start: 2009-04-01Target: 100Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for standard therapy failed Biliary cancer(Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer) patients
Active, not recruitingJPRN-UMIN000001884
Kurume University Cancer Vaccine CenterBiliary cancer (Cholangiocell carcinoma,Gallbladder cancer and Biliary tract cancer)
Start: 2009-04-01Target: 100Updated: 2026-06-29

Related Papers